欧美药物警戒中电子化医疗保健数据的应用研究

摘要/Abstract

摘要： 目的为进一步促进我国药品不良反应监测工作提供思路和参考。方法研究国外利用电子化医疗保健数据开展药物警戒工作的现状和具体应用，归纳与分析其中的不足，为基于我国医院信息系统开展药品不良反应监测、上市后临床研究提出建议。结果与结论利用电子化医疗保健数据开展药品不良反应监测与药物警戒可以从真实世界获取数据，在源头提高报告质量、减少漏报；加强主动监测可以弥补自发报告的不足，是提升工作质量和工作价值的良好途径；应借鉴国外先进经验与技术，加强我国医院信息系统建设与信息综合利用。

关键词: 药品不良反应, 电子化医疗保健数据, 药物警戒, 医院信息系统

Abstract: Objective To provide thought and references for the promotion of ADR monitoring in China. Methods Study on the current state and the practical application by using of data from electronic healthcare records for pharmacovigilance. The shortcomings were summarized and analyzed, suggestions on improving ADR monitoring and post-marketing clinical studies were put forward based on HIS. Results &Conclusion It can get data from the real world to carry out the ADR monitoring by using the HIS, improving the quality of ADR reporting at source and reducing the omission.To strengthen active surveillance can make up for the inadequacy of spontaneous reporting. It is a good way to improve the quality and the value of ADR monitoring. We should draw lessons from foreign advanced experience and technology, strengthen the HIS construction and information comprehensive utilization.

Key words: adverse drug reaction, electronic healthcare records, pharmacovigilance, hospital information system

中图分类号:

R994.11

王玲. 欧美药物警戒中电子化医疗保健数据的应用研究[J]. 中国药物警戒, 2015, 12(3): 156-159.

WANG Ling. Study on Application of Electronic Healthcare Records in Pharmacovigilance in US and EU[J]. Chinese Journal of Pharmacovigilance, 2015, 12(3): 156-159.

参考文献

[1] CFDA.药品不良反应报告和监测管理办法（卫生部令第81号）[EB/OL].（2011-05-04）[2014-06-23]. http://www.sda.gov.cn/WS01/CL0053/62621.html.
[2] 王玲，周晶鑫，张学宁，等.药品不良反应报告数据规整的实践与思考[J].中国药物警戒，2014，11（7）：407-412.
[3] Robb M A,Racoosin J A,Sherman R,et al.The US Food and Drug Administration's Sentinel Initiative:Expanding the horizons of medical product safety [J].Pharmacoepidemiology and Drug Safety, 2012,21（S1）：9-11.
[4] 周晓枫，刘青，蔡兵，等.全球上市后药品主动监测系统概况[J].药物流行病学杂志，2012,21（7）：338-342.
[5] Stang P E,Ryan P B,Racoosin J A,et al. Advancing the science for active surveillance:rationale and design for the Observational Medical Outcomes Partnershop[J]. Annals of Internal Medicine, 2010,153（9）:600-606.
[6] 蔡兵，刘青，周晓枫，等.药品安全主动监测方法简介[J].药物流行病学杂志，2013,22（8）：439-443.
[7] Takahashi Y,Nishida Y,Asai S. Utilization of health care databases for Pharmacoepidemiology[J].Eur J Clin Pharmacol, 2012,68（2）:123-129.
[8] Michael D Murray.Use of Data from Electronic Health Records for pharmacoepidemiology[J].Curr Epidemiol Rep，2014，1:186-193.
[9] Hennessy S.Use of health care databases in pharmacoepidemiology[J].Basic & Clinical Pharmacology & Toxicology，2006,98,311-313.
[10] FDA.Prescription Drug User Fee Act(PDUFA) IV Drug Safety Five Year Plan[EB/OL].（2010-06）[2014-12-23].www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm-
216354.pdf.
[11] 杜丽君.英国国民医疗保健体制下全科医疗模式探析与启示[J].中国农村卫生事业管理，2014，34（10）：1225-1227.
[12] 苏雅茄，张新炯，胡小莹，等.用于药物警戒研究的自动化医疗保健数据库简介[J].药物流行病学杂志，2011,20（10）：536-540.
[13] Louise Wood,Carlos Martinez.The general practice research database:role in pharmacovigilance[J].Drug Safety，2004，27(12):871-881.
[14] Rachel A. Charlton，John G. Weil，Marianne C. Cunnington，et al.Identifying Major Congenital Malformations in the UK General Practice Research Database (GPRD)[J]. Drug Saf，2010，33(9): 741-750.
[15] C.Cooper，M.Steinbuch，R.Stevenson，et al. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK[J].Osteoporos Int，2010，21（4）:569-577.
[16] Eelko Hak，Bianca Mulder，Catharina C. M. Schuiling-Veninga，et al. Use of Acid-Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Crossover Study using the General Practice Research Database[J]. Drug Saf，2013，36（11）:1097-1104.
[17] FDA. FDA's Sentinel Initiative-Background[EB/OL].（2010-01-19）[2014-12-23].http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm.
[18] Yu-Lin Huang，Jinhee Moon，Jodi B Segal. A Comparison of Active Adverse Event Surveillance Systems Worldwide[J]. Drug Saf，2014，37（8）:581-596.
[19] Jose Luis Oliveira,Pedro Lopes,Tiago Nunes，et al. The EU-ADR Web Platform:delivering advanced pharmacovigilance tools[J].Pharmacoepidemiology and drug safety,2013,22(5): 459-467.
[20] Xiaofeng Zhou， Sundaresan Murugesan，Harshvinder Bhullar，et al. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance[J]. Drug Saf，2013， 36（2）:119-134.
[21] Elizabeth B Andrews，Andrea V Margulis，Patricia Tennis，et al. Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases[J]. Curr Epidemiol Rep，2014，1:194-205.
[22] 王玲，黄玲. 药品不良反应报告数据共享平台的建设及对风险沟通的思考[J].中国药物警戒，2014，11（9）:536-541.
[23] 中华人民共和国国务院.国务院关于印发卫生事业发展“十二五”规划的通知（国发〔2012〕57号）[EB/OL].（2012-10-08）[2014-12-23].http://www.gov.cn/zwgk/2012-10/19/content_2246908.htm.